Celcuity Inc. (NASDAQ: CELC) announced modifications to its Phase 3 VIKTORIA-2 clinical trial of gedatolisib for hormone receptor positive, human ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE